SG11201703369WA - Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis - Google Patents

Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis

Info

Publication number
SG11201703369WA
SG11201703369WA SG11201703369WA SG11201703369WA SG11201703369WA SG 11201703369W A SG11201703369W A SG 11201703369WA SG 11201703369W A SG11201703369W A SG 11201703369WA SG 11201703369W A SG11201703369W A SG 11201703369WA SG 11201703369W A SG11201703369W A SG 11201703369WA
Authority
SG
Singapore
Prior art keywords
piperazine
treatment
fumaric acid
multiple sclerosis
ethylene diamine
Prior art date
Application number
SG11201703369WA
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of SG11201703369WA publication Critical patent/SG11201703369WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C07C211/10—Diaminoethanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/593—Dicarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/60—Maleic acid esters; Fumaric acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
SG11201703369WA 2014-10-27 2014-12-29 Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis SG11201703369WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN5330CH2014 2014-10-27
PCT/IN2014/000800 WO2016098119A1 (en) 2014-10-27 2014-12-29 Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
SG11201703369WA true SG11201703369WA (en) 2017-05-30

Family

ID=52595389

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201703369WA SG11201703369WA (en) 2014-10-27 2014-12-29 Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis

Country Status (8)

Country Link
US (1) US9725404B2 (en)
EP (1) EP3212626B1 (en)
JP (1) JP6564868B2 (en)
CN (1) CN107108535B (en)
AU (1) AU2014414316B2 (en)
CA (1) CA2965449C (en)
SG (1) SG11201703369WA (en)
WO (1) WO2016098119A1 (en)

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2807644A (en) 1954-08-20 1957-09-24 Parke Davis & Co Pantethine inhibitors
DE1205972B (en) 1963-08-20 1965-12-02 Merck Ag E Process for the production of a lipoic acid derivative
GB1356470A (en) 1971-06-02 1974-06-12 Seperic Ortho-disubstituted aryl-guanidines process for their preparation and applications thereof
US4011342A (en) 1971-06-02 1977-03-08 Seperic Method and composition for the treatment of hypertension with ortho-disubstituted arylguanidines
JPS5677259A (en) 1979-11-29 1981-06-25 Nippon Chemiphar Co Ltd N-pyridoxyl 5,8,11,14,17-eicosapentaenoic acid amide, and its preparation
JPS57500432A (en) 1980-03-20 1982-03-11
US4404366A (en) 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4412992A (en) 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
US4440763A (en) 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
IT1190727B (en) 1982-03-10 1988-02-24 Ausonia Farma Srl COMPOUND WITH ANALGESIC, ANTI-INFLAMMATORY AND MUCOREGULATING ACTIVITY PROCEDURE FOR ITS PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS
FR2528038B2 (en) 1982-06-04 1985-08-09 Lafon Labor BENZHYDRYLSULFINYLACETAMIDE DERIVATIVES AND THEIR THERAPEUTIC USE
US4564628A (en) 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
US5104887A (en) 1983-02-04 1992-04-14 University Of Iowa Research Foundation Topical ophthalmic imino substituted 2-imino-3-methyl-delta4-1,3,4-thiadiazoline-5-sulfonamides carbonic anhydrase inhibitors
JPS6089474A (en) 1983-10-20 1985-05-20 Toyo Pharma- Kk Morphinan derivative, production thereof and antitumor agent containing said compound
IL73293A (en) 1983-11-04 1988-02-29 Abbott Lab Methyl 2-(alkanamidoalkylsulfonic)ethylthiophosphonate derivatives
IT1213132B (en) 1984-02-02 1989-12-14 Yason Srl ANTIBRONCOPNEUMOPATHIC AGENT.
US4550109A (en) 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
JPS61277618A (en) 1985-06-04 1986-12-08 Suntory Ltd Remedy for autism
YU213587A (en) 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
US4873259A (en) 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
EP0421441B1 (en) 1989-10-06 1995-01-25 Fujirebio Inc. Pantothenic acid derivatives
US5242937A (en) 1990-03-19 1993-09-07 Research Corporation Technologies, Inc. Topically active ocular thiadiazole sulfonamide carbonic anhydrase inhibitors
IT1248702B (en) 1990-06-06 1995-01-26 Yason Srl ANTITUSSIVE AGENT AND MUCOREGULATOR, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS
FR2699077B1 (en) 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application of anticonvulsants in the treatment of neurological lesions linked to trauma.
FR2707637B1 (en) 1993-06-30 1995-10-06 Lafon Labor New acetamide derivatives, their preparation process and their use in therapy.
WO1995022546A1 (en) 1994-02-18 1995-08-24 Cell Therapeutics, Inc. Intracellular signalling mediators
SE9401727D0 (en) 1994-05-18 1994-05-18 Astra Ab New compounds I
FR2722199B3 (en) 1994-07-11 1996-09-06 Univ Picardie Jules Verne Etab VALPROIC ACID DERIVATIVES AND THEIR APPLICATIONS AS MEDICAMENTS
US6156777A (en) 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
IL113459A (en) 1995-04-23 2000-07-16 Electromagnetic Bracing System Electrophoretic cuff apparatus
US6239180B1 (en) 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
NZ334389A (en) 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
TR199901603T2 (en) 1996-11-22 2000-02-21 Elan Pharmaceuticals, Inc. To inhibit the release and/or synthesis of β-amyloid peptide using N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions containing them, and such compounds for methods.
US6414008B1 (en) 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
GB9710351D0 (en) 1997-05-20 1997-07-16 Scotia Holdings Plc Glucosamine fatty acids
JP4395200B2 (en) 1997-10-28 2010-01-06 バンドー化学株式会社 Skin patch sheet and method for producing substrate sheet therefor
NZ333474A (en) 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
HU225741B1 (en) 1998-02-27 2007-07-30 Ube Industries Cyclic amino compounds, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them
JP3761324B2 (en) 1998-05-15 2006-03-29 ヤンマー農機株式会社 Passenger rice transplanter
US6103275A (en) 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
DE19827732A1 (en) 1998-06-22 1999-12-23 Rottapharm Bv Transdermal patch useful for hormone replacement therapy used for treatment of menopausal symptoms
US6846495B2 (en) 1999-01-11 2005-01-25 The Procter & Gamble Company Compositions having improved delivery of actives
EP1905757A1 (en) 1999-04-06 2008-04-02 Sepracor Inc. Derivatives of Venlafaxine and methods of preparing and using the same
US6312716B1 (en) 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
US6262118B1 (en) 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
MXPA02003312A (en) 1999-09-29 2002-10-04 Procter & Gamble Compositions having improved stability.
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
AU2001279064A1 (en) 2000-07-27 2002-02-13 Rutgers, The State University Therapeutic azo-compounds for drug delivery
MXPA03003575A (en) 2000-10-24 2003-07-14 Ajinomoto Kk Process for producing b-form nateglinide crystal.
DE10103506A1 (en) 2001-01-26 2002-08-14 Ingo S Neu Pharmaceutical composition for the treatment of multiple sclerosis
UA81224C2 (en) 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
CA2458015A1 (en) 2001-08-29 2003-03-06 Endo Pharmaceuticals, Inc. Analgetic pyrroline derivatives
US7138133B2 (en) 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
US20040010038A1 (en) 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US20030220344A1 (en) 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
CA2482669A1 (en) 2002-04-15 2003-10-23 Novartis Ag Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
CA2481184A1 (en) 2002-04-16 2003-10-23 Masakazu Kobayashi Medicament for preventing and/or treating chronic rejection
US7060725B2 (en) 2002-05-13 2006-06-13 Janssen Pharmaceutica N.V. Substituted sulfamate anticonvulsant derivatives
GB0223224D0 (en) 2002-10-07 2002-11-13 Novartis Ag Organic compounds
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
CN101413143B (en) 2002-12-19 2013-09-18 斯克里普斯研究学院 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
DE602004015257D1 (en) 2003-02-14 2008-09-04 Pf Medicament USE OF THE (1S, 2R) -MILNACIPRANE ENANTIOMER FOR THE MANUFACTURE OF A MEDICAMENT
UA81657C2 (en) 2003-03-04 2008-01-25 Орто-Макнейл Фармасьютикел, Инк. Normal;heading 1;heading 2;PROCESS FOR THE PREPARATION OF ANTICONVULSANT DERIVATIVES OF TOPIRAMATE
NZ601772A (en) 2003-07-29 2012-10-26 Signature R & D Holdings Llc Amino Acid Prodrugs
SI1677767T1 (en) 2003-10-14 2011-11-30 Xenoport Inc Crystalline form of gamma-aminobutyric acid analog
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
NZ547401A (en) 2003-11-28 2008-06-30 Sankyo Co Cyclic amine derivative having heteroaryl ring
DE10361259A1 (en) 2003-12-24 2005-07-28 Schwarz Pharma Ag Use of Rotigotine in Early Stage Parkinson's Disease to Prevent Further Neuronal Loss
CN1248690C (en) 2004-03-25 2006-04-05 华中师范大学 Oral preparation containing ranolazine hydrochloride for treating cardiovascular disease
CA2561672A1 (en) 2004-04-07 2005-12-08 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
EA011423B1 (en) 2004-04-29 2009-02-27 Колдуэлл Гейлер, Инк. Topical methadone compositions and methods for using the same
CN1672678A (en) 2004-05-03 2005-09-28 深圳微芯生物科技有限责任公司 Separation and extraction of natural active long-chain fatty acid component for preventing and treating prostatosis and the prepn and application of its medicine prepn
PT1751087E (en) 2004-06-04 2012-09-10 Xenoport Inc Levodopa derivatives, and compositions and uses thereof
CN100455560C (en) 2004-06-09 2009-01-28 中国人民解放军军事医学科学院放射医学研究所 Medicine precursor containing long chain fatty acyl group substituted venlafaxine and its prepn and use
WO2006096996A1 (en) 2005-03-18 2006-09-21 Ripped Formulations Ltd. Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
BRPI0612796A2 (en) 2005-05-11 2010-11-30 Nycomed Gmbh combination of a pde4 inhibitor and a tetrahydrobiopterin derivative
DE102005022276A1 (en) 2005-05-13 2006-11-16 Ellneuroxx Ltd. Derivatives of dihydroxyphenylalanine
US20060270635A1 (en) 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
WO2006125293A1 (en) 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
TW200720252A (en) 2005-05-27 2007-06-01 Sankyo Co Cyclic amine derivative having substituted alkyl group
WO2007006307A2 (en) * 2005-07-07 2007-01-18 Aditech Pharma Ab Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
US20080262053A1 (en) 2005-10-18 2008-10-23 Juergen Reess Use of Pramipexole for Treating Moderate to Severe Restless Legs Syndrome (Rls)
AU2007208681B2 (en) 2006-01-27 2010-04-08 Asahi Kasei Pharma Corporation Medicine for transnasal administration
WO2007121188A2 (en) 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
EP1870395A1 (en) 2006-06-19 2007-12-26 KRKA, D.D., Novo Mesto Process for preparation of o-desmethylvenlafaxine and its analogue
US7943666B2 (en) 2006-07-24 2011-05-17 Trinity Laboratories, Inc. Esters of capsaicin for treating pain
US7645767B2 (en) 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
TW200817048A (en) 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
CN100573950C (en) 2006-12-14 2009-12-23 财团法人工业技术研究院 Phase change memory apparatus and manufacture method thereof
CN104107177A (en) 2006-12-14 2014-10-22 诺普生物科学有限责任公司 Compositions and methods of using (r)-pramipexole
CA2673511A1 (en) 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
JP2010515747A (en) 2007-01-12 2010-05-13 ビオマリン プハルマセウトイカル インコーポレイテッド Tetrahydrobiopterin prodrug
ES2319024B1 (en) 2007-02-13 2009-12-11 Quimica Sintetica, S.A. PROCEDURE FOR OBTAINING ENTACAPONA SUBSTANTIALLY FREE OF ISOMERO Z, ITS SYNTHESIS INTERMEDIATES AND NEW CRYSTAL FORM.
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
MX370608B (en) 2007-05-01 2019-12-18 Concert Pharmaceuticals Inc Morphinan compounds.
EP1997493A1 (en) 2007-05-28 2008-12-03 Laboratorios del Dr. Esteve S.A. Combination of a 5-HT7 receptor ligand and an opioid receptor ligand
WO2009002297A1 (en) 2007-06-22 2008-12-31 Gluconova Llc Halide-free glucosamine-acidic drug complexes
US20090075942A1 (en) 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched fosamprenavir
CN101390854A (en) 2007-09-21 2009-03-25 北京德众万全药物技术开发有限公司 Medical composition containing riluzole
WO2009056791A1 (en) 2007-11-02 2009-05-07 Pliva Hrvatska D.O.O. Processes for preparing pharmaceutical compounds
US20090118365A1 (en) 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
CN101186583B (en) 2007-12-20 2011-05-11 吉林大学 Methyl 2-(2-(2,6-dichlorophenylamino)phenyl)acetate and its synthesizing method and application
US20100081713A1 (en) 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
CN102512405B (en) 2008-04-30 2015-08-05 上海医药工业研究院 One class long-chain fatty acid derivative or the plant extract containing it are preparing the application in the medicine suppressing activity of aromatizing enzyme
KR100990949B1 (en) 2008-06-09 2010-10-29 엔자이텍 주식회사 Method for Preparing Clopidogrel and Derivatives Thereof
EP2813486B1 (en) 2008-07-08 2017-10-25 Catabasis Pharmaceuticals, Inc. Fatty acid acetylated salicylates and their uses
DK2334378T3 (en) 2008-08-19 2014-07-07 Xenoport Inc Methyl hydrogen fumarate prodrugs, pharmaceutical compositions thereof and methods of use
CA2734972C (en) 2008-08-22 2017-03-28 Wockhardt Research Centre An extended release pharmaceutical composition of entacapone or salts thereof
WO2010073124A2 (en) 2008-12-26 2010-07-01 Actavis Group Ptc Ehf Processes for preparing highly pure rotigotine or a pharmaceutically acceptable salt thereof
BRPI0901298A2 (en) 2009-04-06 2011-01-04 Ems Sa phthalimide derivatives of nonsteroidal antiinflammatory compounds and / or modulators of tnf- (alpha), process for obtaining them, pharmaceutical compositions containing them and their uses in the treatment of inflammatory diseases
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2010147666A1 (en) 2009-06-19 2010-12-23 Memorial Sloan-Kettering Cancer Center Compounds useful as carbonic anhydrase modulators and uses thereof
WO2011017800A1 (en) 2009-08-10 2011-02-17 Bellus Health (International) Limited Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid
CN102002053A (en) 2009-09-02 2011-04-06 陕西合成药业有限公司 Tetrahydro thienopyridine derivative for treating
CN101717392A (en) 2009-10-09 2010-06-02 苏州凯达生物医药技术有限公司 Method for preparing rotigotine and derivative thereof
CN102050815B (en) 2009-11-06 2014-04-02 北京美倍他药物研究有限公司 Dabigatran ester derivatives as prodrug
CN101724934B (en) 2009-11-10 2012-07-04 东华大学 Medicinal fibre used for treating cutaneous inflammation and pain, preparation and application thereof
ES2364011B1 (en) 2009-11-20 2013-01-24 Gp Pharm, S.A. CAPSULES OF PHARMACEUTICAL ACTIVE AND ESTERS OF POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES.
NZ601698A (en) 2010-01-08 2015-04-24 Catabasis Pharmaceuticals Inc Fatty acid fumarate derivatives and their uses
DK2525830T3 (en) 2010-01-22 2016-08-15 Ascendis Pharma As DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES
RU2436772C2 (en) 2010-01-28 2011-12-20 Закрытое акционерное общество "НПК ЭХО" 4[(4'-nicotinoylamino)butyroylamino]butanoic acid, exhibiting nootropic activity, and method of producing said compound
WO2011106688A1 (en) 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
SG10201501575VA (en) * 2010-03-03 2015-04-29 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
US20110300190A1 (en) 2010-06-08 2011-12-08 Krisani Biosciences (P) Ltd Compound, composition and uses thereof
KR101943812B1 (en) 2010-07-12 2019-01-31 사노피-아벤티스 도이칠란트 게엠베하 Aqueous composition comprising bromhexine
US20120046272A1 (en) 2010-08-23 2012-02-23 Grunenthal Gmbh Novel Therapeutic Compounds
WO2012027543A1 (en) 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof
CN101921245B (en) 2010-08-30 2012-04-18 中国人民解放军军事医学科学院卫生学环境医学研究所 Sulfonamides compound for inhibiting carbonic anhydrase II and synthesis method and application thereof
PT2632451T (en) 2010-10-29 2017-12-14 Algiax Pharmaceuticals Gmbh Use of malononitrilamides in neuropathic pain
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
WO2012115695A1 (en) 2011-02-25 2012-08-30 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
CA2836480A1 (en) * 2011-05-26 2012-11-29 Biogen Idec Ma Inc. Methods of treating multiple sclerosis and preserving and/or increasing myelin content
WO2013008182A1 (en) 2011-07-10 2013-01-17 Mahesh Kandula Prodrugs of gaba analogs
CN102336767A (en) 2011-07-11 2012-02-01 华东理工大学 Method for preparing high-purity chiral alpha-substituted-6,7-thiaindan[3,2-c]pyridine derivative
WO2013017974A1 (en) 2011-07-30 2013-02-07 Mahesh Kandula Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases
WO2013024376A1 (en) 2011-08-16 2013-02-21 Mahesh Kandula Compositions and methods for the treatment of atherothrombosis
WO2013027150A1 (en) 2011-08-21 2013-02-28 Mahesh Kandula Compositions and methods for the treatment of parkinson's disease
JP6189333B2 (en) * 2012-02-07 2017-08-30 バイオジェン エムエー インコーポレーテッド Pharmaceutical composition containing dimethyl fumarate
CN102633799B (en) 2012-04-10 2014-06-25 凯莱英医药集团（天津）股份有限公司 Method for synthesizing sapropterin dihydrochloride from racemate intermediate separation route
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US20150133533A1 (en) 2012-05-08 2015-05-14 Mahesh Kandula Compositions and methods for the treatment of cough
WO2013168022A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treating atherothrombosis
JP2015521184A (en) 2012-05-10 2015-07-27 セリックスビオ プライヴェート リミテッド Compositions and treatments for the treatment of metabolic syndrome
JP2015518854A (en) * 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of multiple sclerosis
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
CN102827131B (en) * 2012-09-10 2015-09-23 四川大学 Isoflavones amino formate compounds, Preparation Method And The Use

Also Published As

Publication number Publication date
CA2965449C (en) 2020-11-10
EP3212626B1 (en) 2018-11-07
CN107108535A (en) 2017-08-29
CN107108535B (en) 2020-04-28
US9725404B2 (en) 2017-08-08
CA2965449A1 (en) 2016-06-23
AU2014414316A1 (en) 2017-06-08
JP6564868B2 (en) 2019-08-21
NZ732044A (en) 2021-09-24
AU2014414316B2 (en) 2020-04-09
WO2016098119A1 (en) 2016-06-23
JP2017533954A (en) 2017-11-16
US20160115115A1 (en) 2016-04-28
EP3212626A1 (en) 2017-09-06

Similar Documents

Publication Publication Date Title
HK1249107A1 (en) Antiviral beta-amino acid ester phosphodiamide compounds
IL251932A0 (en) Benzylpropargylether as nitrification inhibitors
IL248605A0 (en) Medical devices with non-uniform coatings for enhanced echogenicity
PL3122349T3 (en) Compositions for the treatment of autodigestion
PL2990398T3 (en) Hydrophilic polyaspartic acid ester
ZA201700034B (en) Process for the preparation of 3-hydroxypicolinic acids
DK3200779T3 (en) Novel anthranilic acid derivatives
EP3199529A4 (en) Salt of dicarboxylic acid compound
GB201416838D0 (en) Production of an aromatic dicarboxylic acid
IL259073A (en) 3'-substituted-abscisic acid derivatives
PL3183228T3 (en) Process for the purification of acrylic acid
GB201417636D0 (en) Production of an aromatic dicarboxylic acid
SG11201703369WA (en) Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
IL251421A0 (en) Use of neridronic acid or of its salt for the treatment of osteoarthrosis
TWI560541B (en) Liquid coolant supply
PL3164110T3 (en) Pharmaceutical compositions for the treatment of psoriasis
EP2998368A4 (en) Biocide formulation able to prevent the proliferation of microorganisms on surfaces
PL2975004T3 (en) Acid wastewater treatment
GB201417871D0 (en) Production of an aromatic dicarboxylic acid
PT2979694T (en) Dimercaptosuccinic acid for the treatment of multidrug resistant bacterial infections
GB201417735D0 (en) Production of an aromatic dicarboxylic acid
GB201417703D0 (en) Production of an aromatic dicarboxylic acid
GB201417621D0 (en) Production of an aromatic dicarboxylic acid
TH1501006529B (en) Equipment for increasing the amount of gamma-aminobutyric acid.
TH1501006499A (en) dicarboxylic acid compound